Remedor Biomed Overview

  • Founded
  • 2009

Founded
  • Status
  • Private

  • Employees
  • 5

Employees
  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

Remedor Biomed General Information

Description

Developer of a biomedical technology platform based on the combination of two naturally-occurring glycoproteins: erythropoietin (EPO) and fibronectin (FN) designed for revolutionizes complex wound treatment. The company develops a formulation, based on erythropoietin and fibronectin, for therapeutical use in tissue regeneration in the processes of wound healing and bone repair, enabling customers to safe and effective pharmaceutical solutions for wound healing.

Contact Information

Website
remedor.com
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Social/Platform Software
Primary Office
  • 12, HaAvoda Street
  • Nof HaGalil
  • Nof HaGalil
  • Israel
+972 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Remedor Biomed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Startup
To view Remedor Biomed’s complete valuation and funding history, request access »

Remedor Biomed Patents

Remedor Biomed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016314611-A1 Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations Active 04-Sep-2015 000000000
JP-2020180137-A Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of those formulations Pending 04-Sep-2015 000000000
AU-2016314611-B2 Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations Active 04-Sep-2015 00000000
AU-2016314611-C1 Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations Active 04-Sep-2015 00000000
CA-3035830-A1 Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations Pending 04-Sep-2015 A61K9/06
To view Remedor Biomed’s complete patent history, request access »

Remedor Biomed Executive Team (3)

Name Title Board Seat Contact Info
Saher Remedor Ph.D Founder, Chief Technology Officer & Chief Executive Officer
Nicola Downes Chief Financial Officer
You’re viewing 2 of 3 executive team members. Get the full list »

Remedor Biomed Board Members (7)

Name Representing Role Since
Amin Fares Self Board Member 000 0000
Luc Teot MD Self Board Member 000 0000
Noaz-Bar Nir Self Board Member 000 0000
Omar Alwan Self Board Member 000 0000
Paul Liu MD Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Remedor Biomed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Remedor Biomed Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Next Generation Technology Venture Capital Minority 000 0000 000000 0
To view Remedor Biomed’s complete investors history, request access »